<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Currently, there is no validated monitoring technique for predicting bleeding risk in direct oral anticoagulant (DOAC) patients, and the dental literature is based largely on case reports and expert views. This study aims at addressing the following questions: “Should they be stopped before the procedure?” and “What is the correct protocol to follow while ingesting DOACs?” There are presently no dental treatment standards for patients using new oral anticoagulants, and bleeding management recommendations are mainly based on professional opinions and clinical observations rather than well conducted studies or laboratory results. Some of the first DOACs were rivaroxaban, apixaban, edoxaban, and dabigatran. DOACs are now being used to treat patients who were previously taking conventional anticoagulants, and as a result, more dentists will be treating DOAC patients. There is currently no validated monitoring test for estimating bleeding risk in DOAC patients, and the dental literature is primarily on case reports and expert opinions. Prior to dental treatment, it is uncertain whether the DOACs should be continued, partially discontinued for 1 day, or fully interrupted for more than 2 days.</p>
</abstract>

Currently, there is no validated monitoring technique for predicting bleeding risk in direct oral anticoagulant (DOAC) patients, and the dental literature is based largely on case reports and expert views. This study aims at addressing the following questions: “Should they be stopped before the procedure?” and “What is the correct protocol to follow while ingesting DOACs?” There are presently no dental treatment standards for patients using new oral anticoagulants, and bleeding management recommendations are mainly based on professional opinions and clinical observations rather than well conducted studies or laboratory results. Some of the first DOACs were rivaroxaban, apixaban, edoxaban, and dabigatran. DOACs are now being used to treat patients who were previously taking conventional anticoagulants, and as a result, more dentists will be treating DOAC patients. There is currently no validated monitoring test for estimating bleeding risk in DOAC patients, and the dental literature is primarily on case reports and expert opinions. Prior to dental treatment, it is uncertain whether the DOACs should be continued, partially discontinued for 1 day, or fully interrupted for more than 2 days.

Clinical Implication of the New Anticoagulants in Dentistry

Acta Medica Transilvanica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Clinical Implication of the New Anticoagulants in Dentistry"}

Currently, there is no validated monitoring technique for predicting bleeding risk in direct oral anticoagulant (DOAC) patients, and the dental literature is...

Clinical Implication of the New Anticoagulants in Dentistry

Data publikacji: 24 sty 2022

Zakres stron: 69 - 71

Otrzymano: 08 paź 2021

Przyjęty: 02 lis 2021

DOI: https://doi.org/10.2478/amtsb-2021-0078

Słowa kluczowe
DOAC, oral surgery, dentistry, risk

© 2021 Cristina Adriana Dahm Tataru et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Clinical Implication of the New Anticoagulants in Dentistry

Data publikacji: 24 sty 2022

Zakres stron: 69 - 71

Otrzymano: 08 paź 2021

Przyjęty: 02 lis 2021

DOI: https://doi.org/10.2478/amtsb-2021-0078

Słowa kluczoweDOAC, oral surgery, dentistry, risk

© 2021 Cristina Adriana Dahm Tataru et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Słowa kluczowe
DOAC, oral surgery, dentistry, risk